Baxter International Stock Price and Value Analysis

Baxter International (NYSE:BAX) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Baxter International to reach your target.

Target type

BAX Free Cash Flow Trend

Free Cash Flow trendline for BAX
Free Cash Flow trendline for Baxter International
CSV

Based on historical returns, we believe that Baxter International can grow its free cash at a rate of about 7%. That's positive!

AdvantagesDisadvantages
  • This company has fluctuating growth.
  • This company is making money at a decent rate.
  • This stock is available at a great discount!
  • This company is very stable.
  • This company has a low dividend yield.

Inside the BAX Numbers

BAX Price
(Baxter International stock price per share)
$25.39
[?] BAX Fair Price
(based on intrinsic value)
$65.48
[?] BAX Safety Price (based on a variable margin of safety) $52.38
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 21% higher than other Healthcare stocks
[?] PE Ratio versus Industry 1% higher than other Medical Devices stocks
[?] Cash Yield 11.40%
[?] Free Cash Flow Jitter 29%
[?] Dividend Yield 0.16% (tax impact)
Shares Shorted 23,674,982

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 23,674,982 shares shorted. With 514,657,977 shares available for purchase and an average trading volume over the past 10 trading days of 4,655,350, it would take at least 5.1 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 10456 1,613
2008 10456 1,692
2009 10456 2,022
2010 10456 2,097
2011 10456 1,900
2012 10456 2,096
2013 10456 2,237
2014 10456 2,272
2015 10456 838
2016 10456 770
2017 10456 939
2018 10456 1,251
2019 10456 1,384
2020 10456 1,188
2021 10456 1,548
2022 10456 585
2023 10456 1,145
2024 10456 488
2025 10456 353

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 16 fiscal years from 2007 to 2025 with positive net income, operating cash flow totaled $38,144 million against net income of $30,529 million, or 1.25 times. Net income was negative in 3 of the 19 years, and those years are left out of the ratio.

In 2025, net income was -$957 million and operating cash flow was $845 million, so no ratio is shown for that year.

In 2025, capital expenditures were $513 million, 60.7% of operating cash flow of $845 million, which leaves an estimated $332 million after capex. Across the 19 years with reported capex, it averaged 34.3% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2007 1,707 2,305 692 1.35
2008 2,014 2,515 954 1.25
2009 2,205 2,909 1,014 1.32
2010 1,420 3,003 963 2.11
2011 2,224 2,817 960 1.27
2012 2,326 3,106 1,161 1.34
2013 2,012 3,198 706 1.59
2014 2,497 3,215 925 1.29
2015 968 1,771 911 1.83
2016 4,965 1,654 719 0.33
2017 602 1,714 616 2.85
2018 1,546 2,017 659 1.30
2019 1,001 2,104 696 2.10
2020 1,102 1,868 709 1.70
2021 1,284 2,222 691 1.73
2022 -2,433 1,211 377 n/a
2023 2,656 1,726 432 0.65
2024 -649 1,019 446 n/a
2025 -957 845 513 n/a

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $9,650 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $4,482 million, 46.4% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 9 of those 10 years.

In 7 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $5,710 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends paid were $348 million, 98.5% of estimated free cash flow of $353 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 770 268 292 560 72.8%
2017 939 315 564 879 93.7%
2018 1,251 376 2,452 2,828 226.1%
2019 1,384 423 1,270 1,693 122.3%
2020 1,188 473 500 973 81.9%
2021 1,548 530 600 1,130 73.0%
2022 585 573 32 605 103.5%
2023 1,145 586 n/a 586 51.2%
2024 488 590 n/a 590 120.9%
2025 353 348 n/a 348 98.5%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $11,263 million in 2007 and $11,244 million in 2025, a compound annual growth rate of 0.0% over 18 years.

Revenue rose 5.7% from 2024 to 2025.

Our estimated free cash flow was $353 million in 2025, 3.1% of revenue. In 2007 the estimated margin was 14.3%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 11,263 1,613 14.3%
2008 12,348 1,692 13.7%
2009 12,562 2,022 16.1%
2010 12,843 2,097 16.3%
2011 13,893 1,900 13.7%
2012 13,936 2,096 15.0%
2013 9,413 2,237 23.8%
2014 10,719 2,272 21.2%
2015 9,968 838 8.4%
2016 10,163 770 7.6%
2017 10,561 939 8.9%
2018 11,099 1,251 11.3%
2019 11,362 1,384 12.2%
2020 11,673 1,188 10.2%
2021 12,146 1,548 12.7%
2022 10,057 585 5.8%
2023 10,360 1,145 11.1%
2024 10,636 488 4.6%
2025 11,244 353 3.1%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $1,966 million against total liabilities of $13,953 million, or 14.1% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 69.6% of total assets in 2025, compared with 59.2% in 2008, an increase of 10.4 percentage points.

Stockholders equity was $6,102 million in 2025, compared with $6,291 million in 2008, a fall of 3.0%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 2.3% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 15,405 2,131 9,114 6,291
2009 17,354 2,786 9,934 7,420
2010 17,489 2,685 10,693 6,796
2011 19,073 2,905 12,245 6,828
2012 20,390 3,270 13,412 6,978
2013 25,224 2,733 16,738 8,486
2014 26,138 2,925 17,982 8,156
2015 20,962 2,213 12,097 8,865
2016 15,546 2,801 7,325 8,280
2017 17,111 3,394 8,002 9,116
2018 16,843 2,949 8,977 9,062
2019 18,193 3,335 10,281 7,912
2020 20,019 3,730 11,293 8,726
2021 33,521 2,951 24,400 9,121
2022 28,287 1,621 22,392 5,895
2023 28,276 3,078 19,808 8,468
2024 25,782 1,764 18,758 7,024
2025 20,055 1,966 13,953 6,102

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $25.39, our model's value equals that price if free cash flow grows an average of -12.6 percent a year over the 10 projection years. Our model assumes 6.8 percent a year for this stock, so the price implies growth of -12.6 percent, which is below the 6.8 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

A negative rate means the price matches our model's value only if free cash flow shrinks by that average each year over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $1,498 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $20.31 -20.1%
Current price $25.39 -12.6%
20 percent above the current price $30.47 -7.9%
Our model (stored fair price) $65.48 6.8%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Every one of the 19 fiscal years we have for Baxter International under its current filer shows positive free cash flow.

The latest three years average $662 million in free cash flow against $1,776 million for the earliest three, which is a sharp decline.

Year-to-year variability in free cash flow is uneven, measured at 29%.

With the price at $25.39, Baxter International is below both our safe value ($52.38) and our fair value ($65.48).

The dividend yield for Baxter International is 0.16%.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 21% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 1% above the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to Baxter International, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Baxter International (BAX) 13,135 - 0.2% 11.4% 61% below
Penumbra (PEN) 12,578 80.4 - - 781% above
Globus Medical (GMED) 8,861 16.5 - - 61% above
Teleflex Incorporated (TFX) 6,408 79.6 0.8% 5.7% 24% below
Haemonetics Corporation (HAE) 5,472 53.2 - 1.7% 132% above
Merit Medical Systems (MMSI) 5,053 31.6 - 1.1% 117% above
LivaNova PLC (LIVN) 4,998 26.0 - - 317% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 10456.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: BAX annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in BAX

Does Baxter International have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: BAX

This example shows how we apply the Trendshare checklist to BAX: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 25.39
    • Market cap: $13B
    • EPS: -1.21
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: 11.4%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.